• Taxol/Paclitaxel Consumer Settlement
  State of Ohio v. Bristol-Myers Squibb Co., No. 1:02-Cv-01080 (D.D.C.)
  
  Kinsella/Novak implemented a comprehensive notice program to reach cancer patients who were prescribed Taxol, primarily for breast cancer and ovarian cancer. The program was also directed to families of deceased individuals who were treated with Taxol. The $50 million settlement was designed to compensate consumers who may have been overcharged because Bristol-Myers Squibb, Co. allegedly interfered with the release of a cheaper, generic, form of Taxol. The plan included advertisements in high circulation consumer magazines including Better Homes & Gardens, People and Reader’s Digest. Outreach to dozens of non-profit cancer organizations and Web sites resulted in additional notice through Web sites that Class Members would regularly consult for resource information. Print, audio and visual news releases expanded the coverage beyond paid advertising.
  
  
• In re Buspirone Antitrust Litigation
  M.D.L. No. 1413 (S.D.N.Y.)
  
  In the BuSpar Antitrust Litigation, $93 million was allocated for distribution to individuals who took BuSpar to treat generalized anxiety disorder. Plaintiffs alleged that consumers overpaid for the drug because Bristol-Myers Squibb, Co. delayed market entry of a generic form of BuSpar. Kinsella/Novak implemented a notice program consisting of television advertisements aired on many popular broadcast and cable networks, which included NBC, CBS, Home & Garden Television, and the Lifetime Network, among others. Print advertisements also appeared in high circulation consumer magazines including National Geographic, People, and TV Guide. Print, audio and visual news releases expanded the coverage beyond paid advertising.
  
  
• In re Cardizem CD Antitrust Litigation
  200 F.R.D. 326 (E.D. Mich.)
  
  Kinsella/Novak developed a notice program to reach individuals who were treated for hypertension or high blood pressure with Cardizem CD. A $29 million settlement with Hoechst Marion Roussel, the pharmaceutical company that produces or markets the drug, was negotiated to compensate the drug consumers. Plaintiffs alleged that consumers were forced to pay higher prices for the brand-name drug because Hoechst Marion Roussel delayed the production of a generic alternative. The notice program included advertisements in eight high circulation consumer magazines, including Good Housekeeping, People, and TV Guide. Kinsella/Novak also placed advertisements in Parade, USA Weekend, and Puerto Rican newspapers. Print, audio and visual news releases expanded the coverage beyond paid advertising.
  
  
• Lorazepam/Clorazepate Settlement
  State of Connecticut v. Mylan Laboratories, Inc., M.D.L. No. 1290, Civ. No. 1:98-CV-3115 (TFH), Misc. No. 990276 (D.D.C.) (TFH/JMF)
  
  Over 200,000 consumers received $42 million for overcharges for the prescription drugs Lorazepam and Clorazepate as a result of an innovative notice program. In addition to television and print notice directed primarily to elderly women, twelve major pharmacy chains, and three smaller chains, agreed to mail notice to all customers who purchased the drugs. The notice included an easy-to-complete release and waiver form that allowed the claims administrator to obtain the necessary records to process claims directly from the pharmacies. Point-of-purchase materials were sent to over 53,000 individual pharmacies.
  Click here for a PDF fully describing the notice program.